Phaseline

Companies › Locate Bio

Locate Bio: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LDGraft
b-TCP/rhBMP-2 bone graft substitute
–Phase 1Degenerative Disc Disease LumbarOct 2027
LDGraft 0.5mg/cc rhBMP-2
Recombinant human bone morphogenetic protein-2 (rhBMP-2) bone graft substitute
BMP2Phase 1Degenerative Disc DiseaseDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07858643LDGraftPhase 1Degenerative Disc Disease LumbarOtherOct 2027
NCT06462729LDGraft 0.5mg/cc rhBMP-2Phase 1Degenerative Disc DiseaseOtherDec 2027
NCT06462729LDGraft 0.5mg/cc rhBMP-2Phase 1Degenerative Disc DiseaseOtherDec 2027

Targets

BMP2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.